Quantitative RT-PCR and Western blot immunostaining experiments revealed that c-MYB expression levels are decreased in an imatinib-dependent manner and positively correlate with Separase expression levels in cell lines and in clinical CML samples. Here, MYB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.